SUBSCRIBE
SUBSCRIBE

Preclinical

Policy
Biopharma Update on the Novel Coronavirus: November 17
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
November 16, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Inexpensive Nasal Spray Prevents COVID-19 Infection in Ferrets, Shows Promise for Human Trials
A multi-institutional research team has developed a nasal spray that effectively blocks absorption of the SARS-CoV-2 virus in ferrets with direct contact to infected animals.
November 6, 2020
 · 
3 min read
 · 
Brandon May
Drug Development
Research Roundup: Why Blood Clots in COVID-19 and More
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
November 5, 2020
 · 
5 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: November 3
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
November 3, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: October 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
October 27, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Photo courtesy of Aridis
Business
Aridis CEO Confident Inhaled Antibody Formulation Will Play a Key Role in Controlling COVID-19
Only a fraction of intravenous antibody treatments will make their way to the lungs of COVID-19 patients, which is where the infection is primarily located. Aridis Chief Executive Officer Vu Truong believes his company has a better solution – an inhaled antibody.
October 26, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: October 20
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
October 20, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: October 13
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
October 13, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: October 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
October 6, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Arcturus CEO: Investigational COVID-19 Vaccine Could Play Notable Role in Managing the Pandemic
Arcturus CEO Joseph Payne told BioSpace in an interview that his company’s vaccine candidate is a low-dose, single-shot treatment that generated not only neutralizing antibody titers, but also CD8+ T-cell induction in preclinical studies.
September 22, 2020
 · 
3 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Drug Development
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
April 11, 2024
 · 
6 min read
Drug Development
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
April 11, 2024
 · 
5 min read
Drug Development
Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
April 10, 2024
 · 
3 min read
Drug Development
Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting
April 10, 2024
 · 
4 min read
Drug Development
Aptevo Therapeutics Provides Pipeline Update
April 10, 2024
 · 
12 min read
Drug Development
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 10, 2024
 · 
6 min read
Drug Development
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024
April 10, 2024
 · 
6 min read
Drug Development
Cantargia Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in a Leading Scientific Journal
April 10, 2024
 · 
4 min read
Drug Development
Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
April 10, 2024
 · 
8 min read
Drug Development
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
April 10, 2024
 · 
5 min read
Drug Development
Gennao Bio Debuts Preclinical Data for First-in-Class Antibody-Drug Conjugate from Gene Monoclonal Antibody Platform (GMAB ADC)
April 9, 2024
 · 
3 min read
Drug Development
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
April 9, 2024
 · 
7 min read
Drug Development
Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual Meeting
April 9, 2024
 · 
5 min read
Drug Development
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
April 9, 2024
 · 
8 min read
Drug Development
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 9, 2024
 · 
5 min read
Drug Development
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
April 9, 2024
 · 
10 min read
Drug Development
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
April 9, 2024
 · 
5 min read
Drug Development
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
April 8, 2024
 · 
9 min read
Drug Development
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
April 8, 2024
 · 
5 min read
Drug Development
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
April 8, 2024
 · 
8 min read
Load More